Suppression of TGF-β signaling by phospholipase D

Cell Cycle

Volumn 6, Issue 22, 2007, Pages 2840-2845

  Gadir, Noga ^a   Lee, Evan ^a   Garcia, Avalon ^a   Toschi, Alfredo ^a   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cancer; Cell cycle; mTOR; Phospholipase D; Rapamycin; TGF

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE D; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; ENZYME ACTIVITY; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 37249034085     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.22.4921     Document Type: Article

References (44)

1. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-21.
2. Donovan J, Slingerland J. Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Res 2000; 2:116-24.
3. Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004; 6:13-21.
4. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TβRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 1997; 272:27678-85.
5. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 1997; 94:10669-74.
6. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997; 272:28107-15.
7. Markowitz SD, Dawson DM, Willis J, Willson JK. Focus on colon cancer. Cancer Cell 2002; 1:233-6.
8. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002; 2:25-8.
9. Chen CR, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor-b growth arrest program. Proc Natl Acad Sci USA 2001; 98:992-9.
10. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Beychenok S, Foster DA. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Comm 2003; 302:615-9.
11. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D / mTOR survival signal in human breast cancer cells. Oncogene 2005; 24:672-9.
12. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294:1942-45.
13. Foster DA. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Exp Rev Anticancer Ther 2004; 4:691-701.
14. Foster DA. Regulation of mTOR by phosphatidic acid? Cancer Res 2007; 67:1-4.
15. Hornberger TA, Sukhija KB, Chien S. Regulation of mTOR by mechanically induced signaling events in skeletal muscle. Cell Cycle 2006; 5:1391-6.
16. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4:343-8.
17. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J 2006; 25:58-69.
18. Gadir N, Jackson D, Lee E, Foster DA. Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 2007, (in press).
19. Neshat MS. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98:10314-9.
20. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98:10320-5.
21. van der Poel HG, Hanrahan C, Zhong H, Simons JW. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 2003; 30:380-6.
22. van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells. J Urol 2004; 172:1333-7.
23. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003; 1:789-800.
24. Foster DA. Phospholipase D survival signals as a therapeutic target in cancer. Current Signal Transduction Ther 2006; 1:295-303.
25. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003; 22:3937-42.
26. Shen Y, Xu L, Foster DA. Phospholipase D requirement for receptor-mediated endocytosis. Mol Cell Biol 2001; 21:595-602.
27. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4:257-62.
28. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62:65-74.
29. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000; 103:295-309.
30. Wrighton KH, Min Liang, Brad Bryan, Kunxin Luo, Mingyao Liu, Xin-Hua Feng, Xia Lin. TGF-β independent regulation of myogenesis by SnoN sumoylation. J Biol Chem 2006; 281:38365-75.
31. Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 1999; 13:804-16.
32. Grimm OH, Gurdon JB. Nuclear exclusion of Smad2 is a mechanism leading to loss of competence. Nat Cell Biol 2002; 4:519-22.
33. Ogata H, Sato H, Takatsuka J, De Luca LM. Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated Ras. Cancer Lett 2001; 172:159-64.
34. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor β-1. Growth Factors 1993; 8:23-34.
35. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002; 22:8184-98.
36. 1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene 1996; 13:2447-2457.
37. 1 cell-cycle progression by oncogenes and tumorsuppressor genes. Curr Opin Genet Dev 2002; 12:47-52.
38. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
39. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 2005; 25:7917-25.
40. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett 2006; 580:5647-52.
41. Hui L, Rodrik V, Pielak RM, Zheng Y, Foster DA. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem 2005; 280:35829-35835.
42. Hui L, Abbas T, Pielak R, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol 2004; 24:5677-88.
43. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y, Foster DA. Phospholipase D couples survival and migration signals in response to stress in human breast cancer cells. J Biol Chem 2006; 281:15862-8.
44. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2002; 100:57-70.